SLC2A1 and in situ carcinoma: Of the 127 selected articles (CAIX [9,32-71], GLUT1 [30,31,33,34,36,39,42,45],[46,49,53,62,65,67,69,72-91], CXCR4 [92-121] IGF1R [36,122-156]), we excluded ten articles from the analysis due to (suspected) overlap of study populations [38,43,61,62,94,109,123,139],[143,153], and one article [67] because we could not distinguish between carcinoma in situ and invasive breast cancer.